Online Table 5. Index medications for the SGLT-2i groups, by country and overall South Index therapy, n (%) Singapore Israel Canada Australia Total Korea SGLT-2 168,322 33,890 1363 9736 8032 13,721 235,064 135,803 8408 3503 163,693 Dapagliflozin 1013 (74.3) 4121 (51.3) 10,845 (79.0) (80.7) (24.8) (36.0) (69.6) 19,527 6633 6233 33,510 Empagliflozin 240 (17.6) 877 (10.9) 0 (0.0) (11.6) (19.6) (64.0) (14.3) 3826 Canagliflozin 0 (0.0) 110 (8.1) 0 (0.0) 3034 (37.8) 2876 (21.0) 9846 (4.2) (11.3) 8488 Ipragliflozin 12,992 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21,480 (9.1) (25.0) Luseogliflozin 0 (0.0) 2273 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2273 (1.0) 4262 Tofogliflozin 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4262 (1.8) (12.6) SGLT-2i, sodium-glucose co-transporter-2 inhibitors.
Online Table 5. Index medications for the SGLT-2i groups, by country and overall Index therapy, n (%) South Korea Singapore Israel Canada Australia Total SGLT-2 168,322 33,890 1363 9736 8032 13,721 235,064 Dapagliflozin 135,803 (80.7) 8408 (24.8) 1013 (74.3) 3503 (36.0) 4121 (51.3) 10,845 (79.0) 163,693 (69.6) Empagliflozin 19,527 (11.6) 6633 (19.6) 240 (17.6) 6233 (64.0) 877 (10.9) 0 (0.0) 33,510 (14.3) Canagliflozin 0 (0.0) 3826 (11.3) 110 (8.1) 0 (0.0) 3034 (37.8) 2876 (21.0) 9846 (4.2) Ipragliflozin 12,992 (7.7) 8488 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21,480 (9.1) Luseogliflozin 0 (0.0) 2273 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2273 (1.0) Tofogliflozin 0 (0.0) 4262 (12.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4262 (1.8) SGLT-2i, sodium-glucose co-transporter-2 inhibitors.
1-s2.0-S0735109718335289-mmc1.docx